AMINOCAPROIC ACID - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for aminocaproic acid and what is the scope of patent protection?
Aminocaproic acid
is the generic ingredient in four branded drugs marketed by Epic Pharma Llc, Abraxis Pharm, Baxter Hlthcare, Hospira, Luitpold, Zenara, Hikma, Ajenat Pharms, Amneal, Annora Pharma, Aurobindo Pharma, Carnegie, MSN, Regcon Holdings, Sciegen Pharms, Sunny, Taro, Tp Anda Holdings, Vistapharm Llc, Adaptis, Ani Pharms, and Somerset Theraps Llc, and is included in thirty NDAs. Additional information is available in the individual branded drug profile pages.There are six drug master file entries for aminocaproic acid. Twenty-one suppliers are listed for this compound.
Summary for AMINOCAPROIC ACID
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 22 |
| NDAs: | 30 |
| Drug Master File Entries: | 6 |
| Finished Product Suppliers / Packagers: | 21 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 39 |
| Drug Prices: | Drug price trends for AMINOCAPROIC ACID |
| What excipients (inactive ingredients) are in AMINOCAPROIC ACID? | AMINOCAPROIC ACID excipients list |
| DailyMed Link: | AMINOCAPROIC ACID at DailyMed |
Recent Clinical Trials for AMINOCAPROIC ACID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Zagazig University | NA |
| Minia University | Phase 3 |
| NYU Langone Health | N/A |
Pharmacology for AMINOCAPROIC ACID
| Drug Class | Antifibrinolytic Agent |
| Physiological Effect | Decreased Fibrinolysis |
Medical Subject Heading (MeSH) Categories for AMINOCAPROIC ACID
Anatomical Therapeutic Chemical (ATC) Classes for AMINOCAPROIC ACID
US Patents and Regulatory Information for AMINOCAPROIC ACID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regcon Holdings | AMINOCAPROIC ACID | aminocaproic acid | SOLUTION;ORAL | 215510-001 | Mar 23, 2022 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sunny | AMINOCAPROIC ACID | aminocaproic acid | SOLUTION;ORAL | 213213-001 | Dec 27, 2023 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Hikma | AMICAR | aminocaproic acid | TABLET;ORAL | 015197-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Amneal | AMINOCAPROIC ACID | aminocaproic acid | TABLET;ORAL | 212492-001 | Nov 26, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Annora Pharma | AMINOCAPROIC ACID | aminocaproic acid | SOLUTION;ORAL | 216464-001 | Nov 4, 2022 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch